Affordable & Scalable | High-precision antibody test & promising alternative vaccine for COVID-19

TL;DR

Kovacs, a company founded by United Biomedical, offers highly accurate antibody testing and is developing a safe and scalable synthetic peptide vaccine for COVID-19.

Transcript

hey everyone it's Tony Robbins listen this is part of our program on understanding what's happening with cub in 1902 virus the whole purpose of this program is to bring you some of the greatest experts in the world to share with you what's really going on versus maybe the hype or the fear gets out there and most importantly to talk to you about how... Read More

Key Insights

• 👻 Kovacs' antibody test provides accurate and specific results, allowing for better understanding of COVID-19 exposure and potential immunity.
• 👍 The synthetic peptide vaccine platform developed by Kovacs has a proven track record of safety and scalability, making it a promising solution for COVID-19.
• 👶 Testing and vaccination strategies can help society get back to a new normal by identifying those who are immune and protecting vulnerable populations.
• 💄 The COVID-19 pandemic may have been circulating longer than officially recognized, making testing and understanding prevalence important.
• 💨 The FDA has shown flexibility and willingness to fast-track testing and vaccine development to address the urgent global need for solutions.
• 🧑‍⚕️ Kovacs' focus on democratizing and making treatments accessible and affordable highlights their commitment to global health.

Questions & Answers

Q: What is the difference between Kovacs' antibody test and other rapid antibody tests on the market?

Kovacs' antibody test specifically detects IgG antibodies, which are longer-lasting and provide evidence of past exposure and potential immunity. Rapid tests that detect IgM antibodies may have higher false positive rates and are less specific.

Q: How does Kovacs' vaccine platform work?

Kovacs' vaccine platform uses synthetic peptides to mimic the virus and train the body to develop antibodies and immunity. This approach has been successful in protecting pigs from various infectious diseases and offers scalability and safety.

Q: When will the vaccine be available for human trials?

Kovacs plans to start human trials for the COVID-19 vaccine this summer. If successful, an accelerated pathway could potentially allow for mass distribution by early next year.

Q: How can companies or individuals access the testing and vaccine?

Companies can collaborate with Kovacs to provide testing for employees, while individuals can inquire about testing through their healthcare providers. The vaccine will be made available through healthcare providers and clinical networks.

Summary & Key Takeaways

• Kovacs, a subsidiary of United Biomedical, has been privately held for over 30 years and has extensive experience in diagnostics and vaccines.

• Their antibody test is highly accurate and specifically detects IgG antibodies, providing actionable information about exposure and potential immunity.

• The company has developed a synthetic peptide vaccine platform that has been successful in protecting pigs from various infectious diseases and is now being translated to COVID-19.